Semaglutide may be prescribed to treat type 2 diabetes in people with hemoglobin a1c levels of 6.5 or higher, or to treat the precursor known as pre-diabetes in people with hemoglobin a1c levels of 5.7-6.5
Early preclinical studies in experimental diabetes demonstrated toxicities such as anemia, thrombocytopenia, splenomegaly, lymphadenopathy, lung histiocytosis, mortality with multiple organ pathology, gastrointestinal, and central nervous system toxicity
Semaglutide is prescribed only after a medical evaluation
Understanding Semaglutide Semaglutide, originally developed as a medication for managing type 2 diabetes, belongs to a class of drugs known as GLP-1 receptor agonists
* Contains 36g Biotin in 1 Sachet which is 100% recommended daily intake
1996 Jan 16;61(1):1-18